In this episode, Alta Charo, emerita professor of law and bioethics at the University of Wisconsin–Madison, joins Sullivan for a conversation on the evolving landscape of genome editing and its regulatory implications. Drawing on decades of experience in biotechnology policy, Charo emphasizes the importance of distinguishing between hazards and risks and describes the field's approach to regulating applications of technology rather than the technology itself. The discussion also explores opportunities and challenges in biotech’s multi-agency oversight model and the role of international coordination. Later, Daniel Kluttz, a partner general manager in Microsoft's Office of Responsible AI, joins Sullivan to discuss how insights from genome editing could inform more nuanced and robust governance frameworks for emerging technologies like AI.